{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T04:33:59Z","timestamp":1771907639008,"version":"3.50.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["PP00P3_133657, PP00P3_159269"],"award-info":[{"award-number":["PP00P3_133657, PP00P3_159269"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p\/>\n               <jats:sec>\n                  <jats:title>OBJECTIVES<\/jats:title>\n                  <jats:p>Patient allocation to multimodality treatment in patients with malignant pleural mesothelioma remains a challenge. The aim of this study was to validate our previously established Multimodality Prognostic Score (MMPS) (tumour volume before chemotherapy, histological subtype, C-reactive protein before chemotherapy and tumour progression after chemotherapy) and to extend the score with additional blood parameters for better patient outcome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>Patients with histologically proven malignant pleural mesothelioma and curative intended therapy with clinical stage T1\u2013T3 N0\u2013N2 M0 were eligible. The existing MMPS was validated and further additional blood markers (erythrocytes, neutrophils, monocytes, albumin, gamma-glutamyl transferase and alkaline phosphatase) were evaluated for potential incorporation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>For the validation of the existing MMPS, as the first part of this analysis, 117 patients treated as of September 2011 were included. A total of 88 patients were treated with macroscopic complete resection, whereas 29 patients were treated with palliative or no surgery. Patients treated with macroscopic complete resection and a high MMPS showed statistically significant lower overall survival. In the second part, the extension of the MMPS with additional blood parameters was analysed. Albumin, the only parameter showing evidence for having influence on overall survival, was further added to the extended MMPS. When comparing the performance measures Area under the curve (AUC) and Brier score, the extended score performed better (higher AUC, lower Brier score) than the original MMPS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>The extended score with albumin showed improved performance in comparison to the original score. The extended MMPS also may help allocating patients to surgery.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejcts\/ezac085","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T12:07:49Z","timestamp":1644322069000},"source":"Crossref","is-referenced-by-count":10,"title":["Prospective validation and extension of the Multimodality Prognostic Score for the treatment allocation of pleural mesothelioma patients"],"prefix":"10.1093","volume":"62","author":[{"given":"Daria","family":"Greb","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, University Hospital Zurich , Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3843-1629","authenticated-orcid":false,"given":"Monika","family":"Hebeisen","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University Hospital Zurich , Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Matter","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University Hospital Zurich , Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5900-9040","authenticated-orcid":false,"given":"Isabelle","family":"Opitz","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University Hospital Zurich , Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Lauk","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University Hospital Zurich , Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"key":"2022072905391356700_ezac085-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ejcts\/ezaa158","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","volume":"58","author":"Opitz","year":"2020","journal-title":"Eur J Cardiothorac Surg"},{"key":"2022072905391356700_ezac085-B2","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1378\/chest.113.3.723","article-title":"Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B","volume":"113","author":"Herndon","year":"1998","journal-title":"Chest"},{"key":"2022072905391356700_ezac085-B3","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00432-015-2113-0","article-title":"Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer","volume":"142","author":"Fan","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"2022072905391356700_ezac085-B4","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1097\/JTO.0b013e31822a3740","article-title":"Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy","volume":"6","author":"Kao","year":"2011","journal-title":"J Thorac Oncol"},{"key":"2022072905391356700_ezac085-B5","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s00432-013-1523-0","article-title":"Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma","volume":"139","author":"Yao","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"key":"2022072905391356700_ezac085-B6","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thorax.55.9.731","article-title":"Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems","volume":"55","author":"Edwards","year":"2000","journal-title":"Thorax"},{"key":"2022072905391356700_ezac085-B7","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1097\/JTO.0000000000000661","article-title":"A new prognostic score supporting treatment allocation for multimodality therapy for malignant pleural mesothelioma. A review of 12 years\u2019 experience","volume":"10","author":"Opitz","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2022072905391356700_ezac085-B8","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4149\/neo_2017_114","article-title":"Elevated aspartate aminotransferase and monocyte counts predict unfavorable prognosis in patients with malignant pleural mesothelioma","volume":"64","author":"Zhang","year":"2017","journal-title":"Neoplasma"},{"key":"2022072905391356700_ezac085-B9","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1245\/s10434-013-3418-3","article-title":"Elevated preoperative systemic inflammatory markers predict poor outcome in localized soft tissue sarcoma","volume":"21","author":"Choi","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"2022072905391356700_ezac085-B10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/SLA.0b013e3182602af4","article-title":"Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis","volume":"256","author":"Ghanim","year":"2012","journal-title":"Ann Surg"},{"key":"2022072905391356700_ezac085-B11","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-018-6420-y","article-title":"The C-reactive protein\/albumin ratio may predict the long-term outcome in patients with malignant pleural mesothelioma","volume":"25","author":"Yoshida","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"2022072905391356700_ezac085-B12","volume-title":"Blood-Based Biomarkers in Malignant Pleural Mesothelioma: A Retrospective Analysis","author":"Greb","year":"2020"},{"key":"2022072905391356700_ezac085-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-014-0241-z","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement","volume":"13","author":"Collins","year":"2015","journal-title":"BMC Med"},{"key":"2022072905391356700_ezac085-B14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2022072905391356700_ezac085-B15","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1183\/09031936.00146110","article-title":"Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?","volume":"38","author":"Frauenfelder","year":"2011","journal-title":"Eur Respir J"},{"key":"2022072905391356700_ezac085-B16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1475-2891-9-69","article-title":"Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature","volume":"9","author":"Gupta","year":"2010","journal-title":"Nutr J"},{"key":"2022072905391356700_ezac085-B17","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.ejon.2005.09.007","article-title":"The causes and consequences of cancer-associated malnutrition","volume":"9","author":"Van Cutsem","year":"2005","journal-title":"Eur J Oncol Nurs"},{"key":"2022072905391356700_ezac085-B18","first-page":"1","article-title":"Prognostic value of pretreatment albumin-to-alkaline phosphatase ratio in cancer: a meta-analysis","volume":"2020","author":"Xie","year":"2020","journal-title":"Biomed Res Int"},{"key":"2022072905391356700_ezac085-B19","doi-asserted-by":"crossref","first-page":"6268","DOI":"10.1002\/cam4.3244","article-title":"Predictive value of pretreatment albumin-to-alkaline phosphatase ratio for overall survival for patients with advanced non-small cell lung cancer","volume":"9","author":"Zhou","year":"2020","journal-title":"Cancer Med"},{"key":"2022072905391356700_ezac085-B20","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jhep.2014.04.012","article-title":"Human serum albumin, systemic inflammation, and cirrhosis","volume":"61","author":"Arroyo","year":"2014","journal-title":"J Hepatol"},{"key":"2022072905391356700_ezac085-B21","first-page":"2","article-title":"Ageing, nutrition and immune function","volume":"8","author":"Ahluwalia","year":"2004","journal-title":"J Nutr Health Aging"},{"key":"2022072905391356700_ezac085-B22","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/bjc.2015.241","article-title":"Systemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma","volume":"113","author":"Chang","year":"2015","journal-title":"Br J Cancer"},{"key":"2022072905391356700_ezac085-B23","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1245\/s10434-019-07904-9","article-title":"Comprehensive comparative analysis of prognostic value of systemic inflammatory biomarkers for patients with stage II\/III colon cancer","volume":"27","author":"Suzuki","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"2022072905391356700_ezac085-B24","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1245\/s10434-016-5204-5","article-title":"Postoperative systemic inflammatory response, complication severity, and survival following surgery for colorectal cancer","volume":"23","author":"McSorley","year":"2016","journal-title":"Ann Surg Oncol"}],"container-title":["European Journal of Cardio-Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejcts\/article-pdf\/62\/2\/ezac085\/45180173\/ezac085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejcts\/article-pdf\/62\/2\/ezac085\/45180173\/ezac085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T05:40:16Z","timestamp":1659073216000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejcts\/article\/doi\/10.1093\/ejcts\/ezac085\/6546747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,11]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,7,11]]}},"URL":"https:\/\/doi.org\/10.1093\/ejcts\/ezac085","relation":{},"ISSN":["1010-7940","1873-734X"],"issn-type":[{"value":"1010-7940","type":"print"},{"value":"1873-734X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,3,11]]},"article-number":"ezac085"}}